A phase 3 trial evaluating sotatercept-csrk (Winrevairâ„¢) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...
type I receptor in more than 95% of FOP patients that aberrantly activate BMP signaling by Activin A, a TGF-β ligand. This heterotopic ossification (HO) is typically associated with flare-ups ...
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback